Scholars Central

Conference abstractPublished 17 Sep 2018

Fujifilms microneedle array technology

Authors: Hisahiro Mori

Fujifilm Corporation, Japan

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Fujifilm has been developing microneedle array (MNA) of dissolvable type, from 2011. Followings 2 topics were investigated and published. For future aseptic mass production, Fujifilm owns the facility for manufacturing investigational new drug (capable for aseptic production) and developing mass production technologies. In this presentation, results of animal experiments are mainly reported. 1st topic: MNA incorporating influenza vaccine Ether-split and whole virus particles inactivated with formalin were prepared from two type of influenza virus, A/Puerto Rico/8/1934 (H1N1) (PR8) and A/duck/Hokkaido/Vac-3 (H5N1) (Vac-3). These vaccines were incorporated in MNA. BALB/c mice were vaccinated by MNA or subcutaneous injection. MNA containing ether-split or whole virus particle of PR8 shown higher neutralizing antibodies than subcutaneous injection. MNA containing PR8 of whole virus particle shown immunogenicity at lower vaccine dose, compared to MNA containing PR8 of ether split. Furthermore, survival rates of MNA vaccinated mice were significantly higher than subcutaneously vaccinated mice. Virus titer in lung correlated with neutralizing antibody titer in serum. Similar results were obtained with Vac-3. 2nd topic: MNA incorporating hepatitis B surface antigen (HBsAg) HBsAg was incorporated into MNA with or without adjuvant (saponin QS-21). Yorkshire/Landrace F1 (Y x L) x Duroc swine were vaccinated by MNA or intramuscular injection. Commercial HBsAg vaccine containing Al(OH)3 as adjuvant (Engerix-B) was used as a reference. Non-adjuvanted MNA boost after priming with Engerix-B was non-inferior to the benchmark (twice Engerix-B). MNA worked as booster vaccine, without the use of an adjuvant. However, single MNA priming did not elicit an anti-HBsAg antibody response. For QS-21 adjuvanted MNA, twice MNA administration was non-inferior to the benchmark (twice Engerix-B). Also, single MNA priming was able to elicit an anti-HBsAg antibody response.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Pharmaceutical Care & Health Systems.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmaceutical Care & Health Systems
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Hisahiro Mori”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels